Becton Dickinson settles charges over infusion pump risks, SEC says
Tweet
Share
E-mail
FILE PHOTO: The seal of the U.S. Securities and Exchange Commission is seen at their headquarters in Washington, D.C., U.S., May 12, 2021. Picture taken May 12, 2021. REUTERS/Andrew Kelly/File Photo
WASHINGTON (Reuters) - The U.S. Securities and Exchange Commission said on Monday that it had settled charges with Becton Dickinson and Co. (BD) over allegations it misled investors about risks associated with its Alaris infusion pump.
The SEC said Becton Dickinson agreed to pay a $175 million civil penalty to settle the charges, which also allege that the company overstated its income by failing to disclose the costs of software repairs associated with the pump.BD did not admit to or deny the SEC's charges, but said in a statement that a settlement is the "right course of action to fully resolve this matter and move forward."
BD said the company would not need to issue financial restatements as a result of the settlement.
(Reporting by Caitlin Webber; editing by Rami Ayyub)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rapid Line sees stock surge with no known corporate cause
- Cosmos Health posts 29% revenue rise but widens net loss in Q2 2026
- FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa
Create E-mail Alert Related Categories
Litigation, ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
